LOGYST: Low Grade Serous Ovarian Carcinoma and Uterine Involvement : Should Hysterectomy be the Rule

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Completed
CT.gov ID
NCT05741554
Collaborator
(none)
28
1
13.3
2.1

Study Details

Study Description

Brief Summary

Investigators studied a population of 28 low grade serous ovarian carcinoma treated in Hospices civils de Lyon between 2000 and 2022. The primary objective is to determinate the rate of myometrial involvement by the cancer at pathology examination. Then, investigators compared patients with or without myometrial involvement : survival parameters, predictive factors of myometrial involvement (age, CA 125 level, surgery characteristics, pathology characteristics).

Condition or Disease Intervention/Treatment Phase
  • Other: Rate of myometrial involvement in the population of 28 low grade serous ovarian carcinoma.

Study Design

Study Type:
Observational
Actual Enrollment :
28 participants
Observational Model:
Cohort
Time Perspective:
Retrospective
Official Title:
LOw Grade Serous Ovarian Carcinoma and Uterine Involvement : Should hYSTerectomy be the Rule
Actual Study Start Date :
Sep 1, 2021
Actual Primary Completion Date :
Jun 1, 2022
Actual Study Completion Date :
Oct 10, 2022

Arms and Interventions

Arm Intervention/Treatment
Myometrial involvement

Myometrial involvement by cancer metastasis after pathology examination

Other: Rate of myometrial involvement in the population of 28 low grade serous ovarian carcinoma.
Presence of uterine myometrial metastasis at pathology examination after cytoreductive surgery

No myometrial involvement

Absence of myometrial involvement by cancer metastasis after pathology examination

Other: Rate of myometrial involvement in the population of 28 low grade serous ovarian carcinoma.
Presence of uterine myometrial metastasis at pathology examination after cytoreductive surgery

Outcome Measures

Primary Outcome Measures

  1. Percentage of myometrial involvement [After pathology examination, average 2 to 3 weeks after cytoreductive surgery]

    Myometrial involvement after pathology examination

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
Female
  • Inclusion Criteria :

  • 18 years old or more

  • low grade serous ovarian cancer (MDACC classification)

  • Grade 1 serous ovarian carcinoma (Silverberg classification)

  • Exclusion Criteria :

  • no sufficient data available

  • grade 2 and 3 serous ovarian carcinoma

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospices civils de Lyon Lyon France 69000

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT05741554
Other Study ID Numbers:
  • 22-5035
  • 69HCL23_0175
First Posted:
Feb 23, 2023
Last Update Posted:
Feb 23, 2023
Last Verified:
Feb 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Hospices Civils de Lyon
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 23, 2023